Michael Myers

CIK: 0001959547

Transaction Breakdown

Open Market Buys (P)6 (60.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

QNRX

Quoin Pharmaceuticals, Ltd.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (10 total)

QNRX
Quoin Pharmaceuticals, Ltd.
Aug 31, 2026
Purchase(P)
Direct
20.5K shares at avg. $4.88$100K
QNRX
Quoin Pharmaceuticals, Ltd.
Feb 4, 2026
Award(A)
Share Option (Right to Buy)
Direct
318.8K shares-
QNRX
Quoin Pharmaceuticals, Ltd.
May 29, 2025
Award(A)
Share Option (Right to Buy)
Direct
42.9K shares-
QNRX
Quoin Pharmaceuticals, Ltd.
May 29, 2025
Award(A)
Share Option (Right to Buy)
Direct
42K shares-
QNRX
Quoin Pharmaceuticals, Ltd.
Dec 23, 2024
Purchase(P)
Direct
555.6K shares at avg. $0.45$250K
QNRX
Quoin Pharmaceuticals, Ltd.
Dec 9, 2024
Award(A)
Share Option (Right to Buy)
Direct
536.6K shares-
QNRX
Quoin Pharmaceuticals, Ltd.
Sep 4, 2024
Purchase(P)
Direct
23.6K shares at avg. $0.80$19K
QNRX
Quoin Pharmaceuticals, Ltd.
Sep 4, 2024
Purchase(P)
Direct
8.2K shares at avg. $0.75$6K
QNRX
Quoin Pharmaceuticals, Ltd.
Sep 4, 2024
Purchase(P)
Direct
5.3K shares at avg. $0.66$3K
QNRX
Quoin Pharmaceuticals, Ltd.
Sep 3, 2024
Purchase(P)
Direct
800 shares at avg. $0.62$495.2

		Type	Shares	Price		Ownership
Aug 31, 2026	QNRX Quoin Pharmaceuticals, Ltd.	Purchase(P)	20,490	$4.88	$99,991	Direct
Feb 4, 2026	QNRX Quoin Pharmaceuticals, Ltd.	Award(A) Share Option (Right to Buy)	318,750	-	-	Direct
May 29, 2025	QNRX Quoin Pharmaceuticals, Ltd.	Award(A) Share Option (Right to Buy)	42,857	-	-	Direct
May 29, 2025	QNRX Quoin Pharmaceuticals, Ltd.	Award(A) Share Option (Right to Buy)	42,039	-	-	Direct
Dec 23, 2024	QNRX Quoin Pharmaceuticals, Ltd.	Purchase(P)	555,556	$0.45	$250,000	Direct
Dec 9, 2024	QNRX Quoin Pharmaceuticals, Ltd.	Award(A) Share Option (Right to Buy)	536,603	-	-	Direct
Sep 4, 2024	QNRX Quoin Pharmaceuticals, Ltd.	Purchase(P)	23,572	$0.80	$18,796	Direct
Sep 4, 2024	QNRX Quoin Pharmaceuticals, Ltd.	Purchase(P)	8,200	$0.75	$6,134	Direct
Sep 4, 2024	QNRX Quoin Pharmaceuticals, Ltd.	Purchase(P)	5,322	$0.66	$3,490	Direct
Sep 3, 2024	QNRX Quoin Pharmaceuticals, Ltd.	Purchase(P)	800	$0.62	$495	Direct

1-10 of 10 transactions

About Myers Michael

Myers Michael (SEC CIK 0001959547) files insider reports with the SEC as Chief Executive Officer of Quoin Pharmaceuticals, Ltd. (QNRX).

Signal8 holds 7 ownership filings by Myers Michael, all Form 4s, filed between Sep 5, 2024 and Sep 1, 2026. Those filings report 10 transactions, from Sep 3, 2024 to Aug 31, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Myers Michael's filings is in ASHBURN, VA.

Recent filings by Myers Michael

Aug 31, 2026: Open-market purchase of QNRX shares (Form 4, code P).
Feb 4, 2026: Grant or award of QNRX derivative securities (Form 4, code A).
May 29, 2025: Grants or awards of QNRX derivative securities (2 lines, Form 4, code A).
Dec 23, 2024: Open-market purchase of QNRX shares (Form 4, code P).
Dec 9, 2024: Grant or award of QNRX derivative securities (Form 4, code A).

Other insiders filing for Quoin Pharmaceuticals, Ltd. (QNRX)

LANGER DENNIS, Director
Carter Denise P., Chief Operating Officer
Lawlor Sally Bridget, Chief Financial Officer
Culverwell Anthony James, Director
Cooper Joseph Patrick, Director
SEMBER MICHAEL T, Director

How to read Form 4 transaction codes